Senate Finance Panel’s New Legislative Staffer Kaltenboeck Likes QALYs For Valuing Drugs

 
• By Cathy Kelly

Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.

Finance Committee Chair Wyden Could Be Key Figure In Drug Pricing Legislation • Source: Alamy

More from Pricing Debate

More from Market Access